-
公开(公告)号：US20230381308A1
公开(公告)日：2023-11-30
申请号：US18191712
申请日：2023-03-28
CPC分类号： A61K39/39533 , C07K16/241 , C07K16/2875 , A61P37/00 , A61P1/02 , A61P29/00 , A61K48/005 , C07K16/2809 , C07K2317/56 , A61K2039/505
摘要： Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohn's Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.
-
2.发明申请公开(公告)号：US20230091596A1
公开(公告)日：2023-03-23
申请号：US17814704
申请日：2022-07-25
发明人： David Q. Shih , Stephan R. Targan , Dalin Li , Janine Bilsborough
IPC分类号： C07K16/28 , C07K16/24 , A61K39/395 , C12N15/113 , G01N33/68
摘要： The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
-
3.发明申请公开(公告)号：US20230020356A1
公开(公告)日：2023-01-19
申请号：US17334109
申请日：2021-05-28
发明人： Rebecca Gonsky , Stephan R. Targan
IPC分类号： C12Q1/6883
摘要： Described herein are methods and systems for identifying subpopulations of patients having Crohn's disease, including populations at risk of developing structuring or other severe disease, and populations susceptible to success or failure with surgical intervention. Further provided are therapies useful for treating subpopulations of patients having Crohn's disease.
-
公开(公告)号：US20200149110A1
公开(公告)日：2020-05-14
申请号：US16683141
申请日：2019-11-13
发明人： Stephan R. Targan , Marla C. Dubinsky , Carol J. Landers , Ling Mei , Jerome I. Rotter , Kent D. Taylor
IPC分类号： C12Q1/6883 , G01N33/68
摘要： This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.
-
公开(公告)号：US20160215046A1
公开(公告)日：2016-07-28
申请号：US14900024
申请日：2014-07-18
IPC分类号： C07K16/24 , G01N33/68 , C12Q1/68 , A61K45/06 , A61K39/395
CPC分类号： C07K16/241 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/244 , C07K2317/76 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , G01N33/6863 , G01N2015/149 , G01N2333/70575 , G01N2800/7095
摘要： The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
摘要翻译： 本发明涉及TL1A增强TH17细胞分化，增强TH17细胞IL17分泌的发现。 在一个实施方案中，本发明提供治疗炎性疾病的方法，包括测定TL1A信号谱的存在，并通过施用包含治疗有效剂量的一种或多种TL1A或TH17细胞分化抑制剂的组合物来治疗疾病。 在另一个实施方案中，该疾病的特征在于TH17分化。
-
公开(公告)号：US12110555B2
公开(公告)日：2024-10-08
申请号：US17588089
申请日：2022-01-28
发明人： Stephan R. Targan , Marla C. Dubinsky , Carol J. Landers , Ling Mei , Jerome I. Rotter , Kent D. Taylor
IPC分类号： C12Q1/68 , C12Q1/6883 , G01N33/68
CPC分类号： C12Q1/6883 , G01N33/6893 , C12Q2600/156 , G01N2800/065 , G01N2800/50
摘要： This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.
-
公开(公告)号：US11473061B2
公开(公告)日：2022-10-18
申请号：US16074747
申请日：2017-02-01
发明人： Robert Barrett , Clive Svendsen , Stephan R. Targan , Michael Workman , Dhruv Sareen , Uthra Rajamani
摘要： Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
-
公开(公告)号：US20220290235A1
公开(公告)日：2022-09-15
申请号：US17588089
申请日：2022-01-28
发明人： Stephan R. Targan , Marla C. Dubinsky , Carol J. Landers , Ling Mei , Jerome I. Rotter , Kent D. Taylor
IPC分类号： C12Q1/6883 , G01N33/68
摘要： This invention provides methods of diagnosis, predicting and diagnosing susceptibility to, predicting disease progression and treatment of inflammatory bowel disease (IBD), including Crohn's disease and/or subtypes of Crohn's disease (CD) and/or Ulcerative Colitis (UC). In one embodiment, a method of the invention is practiced by determining the presence or absence of the genetic variants NOD2, TLR8, TLR2, CARD8, CARD15 and/or JAK3 to diagnose, predict and diagnose susceptibility and predict disease progression in an individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA in an individual. In another embodiment, the invention further associates the presence or absence of the risk variants with the expression of anti-Cbir1, anti-OmpC, ASCA, anti-I2 and/or pANCA for the diagnosis, prediction of susceptibility, prediction of disease progression and/or treatment of IBD, including CD and/or UC.
-
公开(公告)号：US20220259320A1
公开(公告)日：2022-08-18
申请号：US17682922
申请日：2022-02-28
发明人： Jeffry D. Watkins , Cindy T. Dickerson , Rafael Rojas , Matthew Reissman , Patricia McNeeley , Janine Bilsborough , Bradley Henkle , Stephan R. Targan
摘要： Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
-
公开(公告)号：US11186872B2
公开(公告)日：2021-11-30
申请号：US16084858
申请日：2017-03-17
发明人： Rebecca Gonsky , Stephan R. Targan , Richard L. Deem , Philip Fleshner , Dermot P. McGovern , Janine Bilsborough
IPC分类号： C12Q1/6883 , C12Q1/6806 , C12Q1/686 , C12Q1/6834
摘要： Described herein are methods of diagnosing inflammatory bowel disease, including but not limited to Crohn's Disease (CD), Ulcerative Colitis (UC), and/or Medically Refractive Ulcerative Colitis (MR-UC), using RNA-SET2, TL1A and/or IFN-Y. The methods may comprise treating inflammatory bowel disease by administering a therapeutically effective amount of a therapeutic agent to a subject. Described further herein are processes for patient identification and/or stratification.
-
-
-
-
-
-
-
-
-
搜索结果
47 条记录 (耗时 0.024 秒)
